BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 23493351)

  • 1. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus.
    Kanerva A; Nokisalmi P; Diaconu I; Koski A; Cerullo V; Liikanen I; Tähtinen S; Oksanen M; Heiskanen R; Pesonen S; Joensuu T; Alanko T; Partanen K; Laasonen L; Kairemo K; Pesonen S; Kangasniemi L; Hemminki A
    Clin Cancer Res; 2013 May; 19(10):2734-44. PubMed ID: 23493351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
    Pesonen S; Diaconu I; Cerullo V; Escutenaire S; Raki M; Kangasniemi L; Nokisalmi P; Dotti G; Guse K; Laasonen L; Partanen K; Karli E; Haavisto E; Oksanen M; Karioja-Kallio A; Hannuksela P; Holm SL; Kauppinen S; Joensuu T; Kanerva A; Hemminki A
    Int J Cancer; 2012 Apr; 130(8):1937-47. PubMed ID: 21630267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans.
    Bramante S; Koski A; Kipar A; Diaconu I; Liikanen I; Hemminki O; Vassilev L; Parviainen S; Cerullo V; Pesonen SK; Oksanen M; Heiskanen R; Rouvinen-Lagerström N; Merisalo-Soikkeli M; Hakonen T; Joensuu T; Kanerva A; Pesonen S; Hemminki A
    Int J Cancer; 2014 Aug; 135(3):720-30. PubMed ID: 24374597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
    Koski A; Kangasniemi L; Escutenaire S; Pesonen S; Cerullo V; Diaconu I; Nokisalmi P; Raki M; Rajecki M; Guse K; Ranki T; Oksanen M; Holm SL; Haavisto E; Karioja-Kallio A; Laasonen L; Partanen K; Ugolini M; Helminen A; Karli E; Hannuksela P; Pesonen S; Joensuu T; Kanerva A; Hemminki A
    Mol Ther; 2010 Oct; 18(10):1874-84. PubMed ID: 20664527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients.
    Cerullo V; Pesonen S; Diaconu I; Escutenaire S; Arstila PT; Ugolini M; Nokisalmi P; Raki M; Laasonen L; Särkioja M; Rajecki M; Kangasniemi L; Guse K; Helminen A; Ahtiainen L; Ristimäki A; Räisänen-Sokolowski A; Haavisto E; Oksanen M; Karli E; Karioja-Kallio A; Holm SL; Kouri M; Joensuu T; Kanerva A; Hemminki A
    Cancer Res; 2010 Jun; 70(11):4297-309. PubMed ID: 20484030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers.
    Du T; Shi G; Li YM; Zhang JF; Tian HW; Wei YQ; Deng H; Yu DC
    Cancer Gene Ther; 2014 Aug; 21(8):340-8. PubMed ID: 25034886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: Results in vitro, in rodents and in humans.
    Bramante S; Kaufmann JK; Veckman V; Liikanen I; Nettelbeck DM; Hemminki O; Vassilev L; Cerullo V; Oksanen M; Heiskanen R; Joensuu T; Kanerva A; Pesonen S; Matikainen S; Vähä-Koskela M; Koski A; Hemminki A
    Int J Cancer; 2015 Oct; 137(7):1775-83. PubMed ID: 25821063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model.
    Li X; Wang P; Li H; Du X; Liu M; Huang Q; Wang Y; Wang S
    Clin Cancer Res; 2017 Jan; 23(1):239-249. PubMed ID: 27435398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocyte-macrophage colony-stimulating factor-armed oncolytic measles virus is an effective therapeutic cancer vaccine.
    Grossardt C; Engeland CE; Bossow S; Halama N; Zaoui K; Leber MF; Springfeld C; Jaeger D; von Kalle C; Ungerechts G
    Hum Gene Ther; 2013 Jul; 24(7):644-54. PubMed ID: 23642239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.
    Santos JM; Heiniö C; Cervera-Carrascon V; Quixabeira DCA; Siurala M; Havunen R; Butzow R; Zafar S; de Gruijl T; Lassus H; Kanerva A; Hemminki A
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimized biodegradable polymeric reservoir-mediated local and sustained co-delivery of dendritic cells and oncolytic adenovirus co-expressing IL-12 and GM-CSF for cancer immunotherapy.
    Oh E; Oh JE; Hong J; Chung Y; Lee Y; Park KD; Kim S; Yun CO
    J Control Release; 2017 Aug; 259():115-127. PubMed ID: 28336378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy.
    Hemminki O; Parviainen S; Juhila J; Turkki R; Linder N; Lundin J; Kankainen M; Ristimäki A; Koski A; Liikanen I; Oksanen M; Nettelbeck DM; Kairemo K; Partanen K; Joensuu T; Kanerva A; Hemminki A
    Oncotarget; 2015 Feb; 6(6):4467-81. PubMed ID: 25714011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
    Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
    Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor-specific T-cell responses induced by oncolytic adenovirus ONCOS-102 (AdV5/3-D24-GM-CSF) in peritoneal mesothelioma mouse model.
    Kuryk L; Møller AW; Garofalo M; Cerullo V; Pesonen S; Alemany R; Jaderberg M
    J Med Virol; 2018 Oct; 90(10):1669-1673. PubMed ID: 29797583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.
    Hemminki O; Diaconu I; Cerullo V; Pesonen SK; Kanerva A; Joensuu T; Kairemo K; Laasonen L; Partanen K; Kangasniemi L; Lieber A; Pesonen S; Hemminki A
    Mol Ther; 2012 Sep; 20(9):1821-30. PubMed ID: 22871667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strengthening of antitumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSF.
    Choi KJ; Zhang SN; Choi IK; Kim JS; Yun CO
    Gene Ther; 2012 Jul; 19(7):711-23. PubMed ID: 21993173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
    Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
    Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.